A group of researchers from the US has reported some exciting results using Talazoparib, a PARP inhibitor. They treated five PALB2 carriers with breast cancer and one carrier with pancreatic cancer, and all cancers responded to the drug. The numbers are very small and more studies need to be done but this is exciting early evidence that PARP inhibitors are effective against PALB2 cancers. The full study can be accessed here:
Gruber, J.J., Afghahi, A., Timms, K. et al. A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes. Nat Cancer (2022). https://doi.org/10.1038/s43018-022-00439-1